Evaluation of ferric and ferrous iron therapies in women with iron deficiency anaemia

Basit Öğe Kaydı
dc.authorscopusid55274431700
dc.authorscopusid55965469200
dc.authorscopusid8842895600
dc.authorscopusid56264100700
dc.authorscopusid7004568106
dc.authorscopusid6603472555
dc.contributor.authorBerber I.
dc.contributor.authorDiri H.
dc.contributor.authorErkurt M.A.
dc.contributor.authorAydogdu I.
dc.contributor.authorKaya E.
dc.contributor.authorKuku I.
dc.date.accessioned2024-08-04T20:02:33Z
dc.date.available2024-08-04T20:02:33Z
dc.date.issued2014
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIntroduction. Different ferric and ferrous iron preparations can be used as oral iron supplements. Our aim was to compare the effects of oral ferric and ferrous iron therapies in women with iron deficiency anaemia. Methods. The present study included 104 women diagnosed with iron deficiency anaemia after evaluation. In the evaluations performed to detect the aetiology underlying the iron deficiency anaemia, it was found and treated. After the detection of the iron deficiency anaemia aetiology and treatment of the underlying aetiology, the ferric group consisted of 30 patients treated with oral ferric protein succinylate tablets (2 × 40 mg elemental iron/day), and the second group consisted of 34 patients treated with oral ferrous glycine sulphate tablets (2 × 40 mg elemental iron/day) for three months. In all patients, the following laboratory evaluations were performed before beginning treatment and after treatment. Results. The mean haemoglobin and haematocrit increases were 0.95 g/dL and 2.62% in the ferric group, while they were 2.25 g/dL and 5.91% in the ferrous group, respectively. A significant difference was found between the groups regarding the increase in haemoglobin and haematocrit values (P < 0.05). Conclusion. Data are submitted on the good tolerability, higher efficacy, and lower cost of the ferrous preparation used in our study. © 2014 Ilhami Berber et al.en_US
dc.identifier.doi10.1155/2014/297057
dc.identifier.issn1687-9104
dc.identifier.scopus2-s2.0-84903649789en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1155/2014/297057
dc.identifier.urihttps://hdl.handle.net/11616/91780
dc.identifier.volume2014en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherHindawi Publishing Corporationen_US
dc.relation.ispartofAdvances in Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectantianemic agenten_US
dc.subjectferritinen_US
dc.subjectferrous glycine sulphateen_US
dc.subjecthemoglobinen_US
dc.subjectiron protein succinylateen_US
dc.subjecttransferrinen_US
dc.subjectunclassified drugen_US
dc.subjectadulten_US
dc.subjectarticleen_US
dc.subjectblood cell counten_US
dc.subjectcomparative studyen_US
dc.subjectconstipationen_US
dc.subjectcontrolled studyen_US
dc.subjectdrug costen_US
dc.subjectdrug efficacyen_US
dc.subjectdrug tolerabilityen_US
dc.subjectdrug withdrawalen_US
dc.subjectepigastric painen_US
dc.subjecterythrocyteen_US
dc.subjectevaluation studyen_US
dc.subjectfemaleen_US
dc.subjectferritin blood levelen_US
dc.subjecthematocriten_US
dc.subjecthemorrhoiden_US
dc.subjecthumanen_US
dc.subjectiron absorptionen_US
dc.subjectiron binding capacityen_US
dc.subjectiron blood levelen_US
dc.subjectiron deficiency anemiaen_US
dc.subjectiron therapyen_US
dc.subjectmajor clinical studyen_US
dc.subjectmalnutritionen_US
dc.subjectmean corpuscular hemoglobinen_US
dc.subjectmean corpuscular volumeen_US
dc.subjectmenorrhagiaen_US
dc.subjectpalliative therapyen_US
dc.subjectrandomized controlled trialen_US
dc.titleEvaluation of ferric and ferrous iron therapies in women with iron deficiency anaemiaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu